One of the unique challenges of living with an invisible illness is figuring out how to tell others. Although I’ve lived with idiopathic pulmonary fibrosis (IPF) for five years, it’s still not easy for me to disclose my condition. Most people wouldn’t know that this life-threatening and relentless disease has…
Anti-fibrotic medications, such as Esbriet (pirfenidone) and Ofev (nintedanib), are not cost-effective treatments for idiopathic pulmonary fibrosis (IPF) in the U.S. due to their high prices, even though they remain the only effective therapies, according to a recent study. The study, “Cost-effectiveness of the anti-fibrotics for…
I’ve found myself daydreaming lately about a return to normal. I long for the days when we didn’t need face masks, when I could see someone’s smile during a conversation, and when hand sanitizer wasn’t the most frequent smell I encountered. Most people who know me would describe me as…
Injuries to the lung from diseases like idiopathic pulmonary fibrosis (IPF) can trigger an abnormal cell response that affects lung cell repair and is associated with excessive tissue scarring, a study showed. Scientists noted that further studies are needed to determine whether this process is reversible, which may lead…
Patients with idiopathic pulmonary fibrosis (IPF) with chronic cough who are being treated with the investigational oral medication NP-120 (ifenprodil) in a small clinical trial tended to experience a reduction in coughing, according to the therapy’s developer Algernon Pharmaceuticals. The company is funding an open-label Phase 2…
I have several roles here at Bionews, the parent company that publishes Pulmonary Fibrosis News and other rare disease websites. I started with this humble column and eventually joined the forums team as a co-moderator. My most recently acquired title is “columns lead,” in which I manage and mentor…
Cudetaxestat (BLD-0409), an experimental medication for idiopathic pulmonary fibrosis (IPF) from Blade Therapeutics, was well-tolerated among healthy volunteers when given in combination with other IPF treatments — specifically nintedanib and pirfenidone — in a Phase 1 study. “These findings provide confidence in the potential to safely co-administer cudetaxestat…
As we approach year three of the COVID-19 pandemic, I am tired. I’m sure we all are. This pandemic fatigue, combined with the January blues, makes it a difficult time of year for many, and leaves the world feeling heavy and dark. While there is no immediate fix, being…
Enrollment has been completed for INTEGRIS-IPF, a Phase 2a trial testing PLN-74809, an experimental oral anti-fibrotic therapy, in people with idiopathic pulmonary fibrosis (IPF). Pliant Therapeutics, the company developing PLN-74809 and sponsoring the trial, said it is expecting top-line results to become available midway through the year. The…
My plan for the holidays was to binge-watch all the Rocky movies. I love this character as played by Sylvester Stallone, and I can relate to how much he struggles to find his way through what life has thrown at him. I particularly identify…
Get regular updates to your inbox.
